Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial (2022)

Peer-Reviewed Study · Patil VM, Menon N, Chatterjee A, Tonse R, Choudhari A, Mahajan A, Puranik AD, Epari S, Jadhav M, Pathak S, Walavalkar R, Krishnatry R, Gupta T, Banavali S, Jalali R · May 27, 2022

Patil VM et al., 2022-05-27: Randomized open-label phase 2 trial adding mebendazole to lomustine or temozolomide in 88 patients with recurrent glioblastoma. It found 9-month overall survival of 36.6% and 45%, below the pre-set 55% benchmark, and no survival advantage.

The addition of MBZ to TMZ or CCNU failed to achieve the pre-set benchmark of 55% 9-month OS.

n/a

Patil VM et al., 2022-05-27: Randomized open-label phase 2 trial adding mebendazole to lomustine or temozolomide in 88 patients with recurrent glioblastoma. It found 9-month overall survival of 36.6% and 45%, below the pre-set 55% benchmark, and no survival advantage. Study type: randomized, open-label, phase 2, two-arm. N=88 (44 per arm). Country: India (Tata Memorial Centre). Dose: temozolomide 200 mg/m2 days 1-5 every 28 days plus mebendazole 1600 mg three times daily; CCNU 110 mg/m2 every 6 weeks plus mebendazole 800 mg three times daily. Funder: Brain Tumor Foundation India, Indian Cooperative Oncology Network, India Cancer Research Consortium/ICMR. Conflicts: V.P. reports grants from Janssen, AstraZeneca, Intas, Natco, Cadila, Eisai and Novartis outside the work; N.M. reports an AstraZeneca grant. Maker: generic mebendazole isoform B, Mebex 100 mg, Cipla. Comparator: the two arms compare mebendazole plus CCNU versus mebendazole plus temozolomide; no mebendazole-free arm. Median OS 6.70 months (TMZ-MBZ) and 6.53 months (CCNU-MBZ); grade 3+ adverse events 18.6% and 9.5%. Study type: randomized trial.